History & Previous Editions

The Swiss RNA Therapeutics Summit brings together stakeholders in the field of RNA Therapeutics from academia, biotechnology, pharma, manufacturing, government, and regulatory bodies with the aim to join forces in this rapidly advancing field. Also, the workshop brings into together companies with potential future employees.

Origin of the Summit

The Idea Of The Workshop Was Born After A Panel Discussion On “RNA Drugs: Applications Beyond Vaccines” At The Swiss Biotech Day In May 2022 In Basel. The Swiss RNA Therapeutics Summit Was For The First Edition A Joint Initiative Of The National Center Of Competence In Research (NCCR) “RNA & Disease: The Role Of RNA In Disease Mechanisms” And The Swiss Biotech Association. Since The Second Edition, The NCCR RNA & Disease Is The Organization Powering The RNA Therapeutics Summit.

First Swiss RNA Therapeutics Summit – January 2023

The first Swiss RNA Therapeutics Summit took place on 26 January 2023 at the University of Bern and was co-organised with the Swiss Biotech Association.

The event brought together more than 180 participants from academia, industry and other sectors.

The programme featured opening remarks by Christian Leumann, Rector of the University of Bern and an expert in oligonucleotide chemistry, as well as keynote lectures by Mustafa Diken, Vice President of Vaccines & Immunology at BioNTech, and Shalini Andersson, Vice President of Oligonucleotide Discovery at AstraZeneca. Panel discussions and company presentations complemented the scientific programme.

We gratefully acknowledge the sponsors, the Oligonucleotide Therapeutics Society and everyone whose contributions made the inaugural Summit a success.

Click here to see the Program, Speakers List and Sponsors of the 2023 Edition

Second Swiss RNA Therapeutics Summit – January 2024

The second Swiss RNA Therapeutics Summit took place on 25 January 2024 in Bern and was fully booked, welcoming more than 200 registered participants. Opening remarks were delivered by Hugues Abriel, Vice-Rector for Research at the University of Bern.

The keynote programme featured Paul Nioi, Senior Vice President of Research at Alnylam Pharmaceuticals, speaking on siRNA therapies for neurological diseases, and Martin Jinek, Professor at the University of Zurich and co-discoverer of CRISPR, presenting on CRISPR genome editing.

We gratefully acknowledge the sponsors, the Oligonucleotide Therapeutics Society and everyone whose contributions made the second Summit a success.

Click here to see Program, Speakers List, and Sponsor of the 2024 Edition